Table 1 Baseline clinico-demographic parameters and health utility scores in GS-US-337-0113 and GS-US-334-0118
LDV/SOF | LDV/SOF + RBV | SOF + RBV | P | All | |
|---|---|---|---|---|---|
N | 171 | 170 | 153 | 494 | |
Age, years | 59.7 ± 9.2 | 59.2 ± 9.5 | 56.8 ± 10.1 | 0.0310 | 58.6 ± 9.7 |
Male | 69 (40.4%) | 73 (42.9%) | 70 (45.8%) | 0.62 | 212 (42.9%) |
HCV genotype 1 | 171 (100.0%) | 170 (100.0%) | 0 (0.0%) | <0.0001 | 341 (69.0%) |
HCV genotype 2 | 0 (0.0%) | 0 (0.0%) | 153 (100.0%) | 153 (31.0%) | |
Treatment-naïve | 83 (48.5%) | 83 (48.8%) | 90 (58.8%) | 0.11 | 256 (51.8%) |
Cirrhosis | 41 (24.0%) | 35 (20.6%) | 17 (11.1%) | 0.0097 | 93 (18.8%) |
History of anxiety | 8 (4.7%) | 4 (2.4%) | 3 (2.0%) | 0.30 | 15 (3.0%) |
History of depression | 3 (1.8%) | 7 (4.1%) | 5 (3.3%) | 0.44 | 15 (3.0%) |
History of insomnia | 24 (14.0%) | 21 (12.4%) | 21 (13.7%) | 0.89 | 66 (13.4%) |